Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in <i>db/db</i> mice: adipogenesis/or oedema?

Abstract

Although muraglitazar has a better glucose lowering profile, it also has a greater potential for weight gain than rosiglitazone. In conclusion, muraglitazar causes both robust adipogenesis and oedema in a 14-day treatment of db/db mice as observed in humans.